Back to Research

Organization profile

Aukera Therapeutics

Aukera Therapeutics is a preclinical-stage biotech organization that specializes in the development of first-in-class RAPTOR inhibitors for the treatment of mTORC1-related pathologies. By leveraging a proprietary AI-driven discovery platform, the company targets rare neurological disorders, cancer, and age-related diseases through selective modulation of cellular growth pathways.26

Basel, SwitzerlandFounded 2021

Overview

1. Executive Summary (Confidence: High)

Aukera Therapeutics GmbH, a 2021 spin-off from the University of Basel’s Biozentrum, is a high-impact player in the geroscience and oncology sector.[26] The company was founded on seminal academic research from the laboratories of Professors Michael N. Hall (the discoverer of TOR) and Timm Maier.[28] Aukera is developing the first "RAPTOR inhibitors" designed to selectively target the mTORC1 signaling network—the cell's primary growth engine—without disrupting the critical survival functions of mTORC2.[26] This selective approach addresses the severe toxicity and efficacy limitations of previous generations of mTOR inhibitors like rapamycin.[29] Officially emerging from stealth in late 2025, the company has raised approximately CHF 4.5 million in funding from investors including Kickfund and Zürcher Kantonalbank.[28] Led by CEO Stefan Imseng, Aukera is currently advancing its lead program into preclinical efficacy studies for Tuberous Sclerosis Complex (TSC) and has a strategic roadmap targeting neurodegeneration and metabolic disorders.[28]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.